Literature DB >> 24037805

Pathology is a necessary and informative tool in oncology clinical trials.

Iris D Nagtegaal1, Nicholas P West, J Han J M van Krieken, Phil Quirke.   

Abstract

Clinical trials are essential for the improvement of cancer care. The complexity of modern cancer care and research require careful design, for which input from all disciplines is necessary. Pathologists should play a key role in the design and execution of modern cancer trials, with special attention to the eligibility, stratification and evaluation of response to therapy. In the current review all these aspects are discussed, with examples from colorectal cancer trials. We describe critical issues in biomarker evaluation and development and emphasize the importance of the role of the pathologist in quality control of cancer treatment.
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  clinical trials; end point; oncology; quality assurance; response; staging; stratification

Mesh：

Year:  2014        PMID： 24037805     DOI： 10.1002/path.4261

Source DB:  PubMed          Journal:  J Pathol        ISSN： 0022-3417            Impact factor:   7.996


  8 in total

1.  Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.

Authors:  Julia Kitz; Emmanouil Fokas; Tim Beissbarth; Philipp Ströbel; Christian Wittekind; Arndt Hartmann; Josef Rüschoff; Thomas Papadopoulos; Elisabeth Rösler; Peter Ortloff-Kittredge; Ulrich Kania; Hans Schlitt; Karl-Heinrich Link; Wolf Bechstein; Hans-Rudolf Raab; Ludger Staib; Christoph-Thomas Germer; Torsten Liersch; Rolf Sauer; Claus Rödel; Michael Ghadimi; Werner Hohenberger
Journal:  JAMA Surg       Date:  2018-08-15       Impact factor: 14.766

2.  Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.

Authors:  Prabhakar Rajan; Jacqueline Stockley; Ian M Sudbery; Janis T Fleming; Ann Hedley; Gabriela Kalna; David Sims; Chris P Ponting; Andreas Heger; Craig N Robson; Rhona M McMenemin; Ian D Pedley; Hing Y Leung
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

3.  Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work.

Authors:  Max Robinson; Jacqueline James; Gareth Thomas; Nicholas West; Louise Jones; Jessica Lee; Karin Oien; Alex Freeman; Clare Craig; Philip Sloan; Philip Elliot; Maggie Cheang; Manuel Rodriguez-Justo; Clare Verrill
Journal:  J Pathol Clin Res       Date:  2018-11-29

4.  Is it time to call for improvement in surgical techniques for minimally invasive radical hysterectomy?

Authors:  Linus Chuang; Pratistha Koirala; Farr Nezhat
Journal:  JSLS       Date:  2020 Jan-Mar       Impact factor: 2.172

5.  Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation.

Authors:  Shujing Jane Lim; Kurinchi Gurusamy; Daniel O'Connor; Abeer M Shaaban; Daniel Brierley; Ian Lewis; David Harrison; Timothy James Kendall; Max Robinson
Journal:  J Pathol Clin Res       Date:  2021-02-26

Review 6.  Digital pathology and artificial intelligence in translational medicine and clinical practice.

Authors:  Vipul Baxi; Robin Edwards; Michael Montalto; Saurabh Saha
Journal:  Mod Pathol       Date:  2021-10-05       Impact factor: 7.842

Review 7.  The Increasing Relevance of Tumour Histology in Determining Oncological Outcomes in Colorectal Cancer.

Authors:  Iris D Nagtegaal; Niek Hugen
Journal:  Curr Colorectal Cancer Rep       Date:  2015

8.  Training and accreditation standards for pathologists undertaking clinical trial work.

Authors:  Gabrielle Rees; Manuel Salto-Tellez; Jessica L Lee; Karin Oien; Clare Verrill; Alex Freeman; Ilaria Mirabile; Nicholas P West
Journal:  J Pathol Clin Res       Date:  2019-02-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.